Sangamo Therapeutics (Sangamo Therapeutics) FCF Margin %

: -2,605.73% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sangamo Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-53.2 Mil. Sangamo Therapeutics's Revenue for the three months ended in Dec. 2023 was $2.0 Mil. Therefore, Sangamo Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -2,605.73%.

As of today, Sangamo Therapeutics's current FCF Yield % is -217.59%.

The historical rank and industry rank for Sangamo Therapeutics's FCF Margin % or its related term are showing as below:

SGMO' s FCF Margin % Range Over the Past 10 Years
Min: -343.57 Med: -115.49 Max: 131.28
Current: -139.59

During the past 13 years, the highest FCF Margin % of Sangamo Therapeutics was 131.28%. The lowest was -343.57%. And the median was -115.49%.

SGMO's FCF Margin % is ranked better than
50.97% of 1030 companies
in the Biotechnology industry
Industry Median: -149.715 vs SGMO: -139.59

Sangamo Therapeutics FCF Margin % Historical Data

The historical data trend for Sangamo Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-161.16

131.28

-231.73

-219.05

-139.59

Sangamo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %																-236.96	-48.43	-969.29	-532.42	-2,605.73

Competitive Comparison

For the Biotechnology subindustry, Sangamo Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics FCF Margin % Distribution

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's FCF Margin % falls into.

Sangamo Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sangamo Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-245.997	/	176.232
	=	-139.59 %

Sangamo Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-53.209	/	2.042
	=	-2,605.73 %

Sangamo Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GBY:Germany

Address

7000 Marina Boulevard, Brisbane, CA, USA, 94005

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Executives

Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney	director	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow	officer: SVP-Chief Development Officer	C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker	director
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby	officer: SVP, Gen. Counsel & Secretary	7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb	officer: EVP & General Counsel	5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot	officer: SVP, Chief Scientific Officer	7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott	officer: SVP, Head of Development	7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier	officer: EVP, Technical Operations	7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung	officer: EVP Chief Business Officer	7000 MARINA BLVD, BRISBANE CA 94005